Get the Stockscreener App
45.28
0.85%
0.38
Pre-market:
45.82
0.54
+1.19%
Qiagen Nv stock is traded at $45.28, with a volume of 1.45M.
It is up +0.85% in the last 24 hours and up +4.98% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$44.90
Open:
$44.95
24h Volume:
1.45M
Relative Volume:
1.06
Market Cap:
$9.81B
Revenue:
$1.98B
Net Income/Loss:
$83.59M
P/E Ratio:
121.07
EPS:
0.374
Net Cash Flow:
$502.31M
1W Performance:
+3.26%
1M Performance:
+4.98%
6M Performance:
+1.69%
1Y Performance:
+0.05%
1-Day Range:
$44.74
$45.39
1-Week Range:
$43.99
$45.41
52-Week Range:
$37.74
$49.30
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
45.28 | 9.50B | 1.98B | 83.59M | 502.31M | 0.374 |
|
TMO
Thermo Fisher Scientific Inc
|
399.93 | 152.34B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
192.06 | 135.39B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
525.83 | 41.54B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
112.76 | 31.61B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
142.78 | 24.31B | 15.50B | 1.33B | 2.16B | 7.34 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Here's Why Qiagen (QGEN) is a Strong Value Stock - Yahoo Finance
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances - Nasdaq
Qiagen expands portfolio for minimal residual disease testing in oncology - BioSpectrum Asia
Qiagen N.V. (QGEN) Expands MRD Testing with Tracer and Foresight Partnerships - MSN
QIAGEN expands portfolio for MRD testing in oncology with two partnerships - Seeking Alpha
Foresight Diagnostics and Qiagen Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - marketscreener.com
Qiagen Enters Partnerships, Expands Portfolio for Minimal Residual Disease Testing in Oncology - marketscreener.com
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships - Business Wire
Foresight Diagnostics And Qiagen Announce Strategic Partnership To Advance Development Of Companion Diagnostic Kits For Lymphoma - marketscreener.com
Qiagen (QGEN) Forms Strategic Alliance with Foresight Diagnostics | QGEN Stock News - GuruFocus
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - marketscreener.com
Equities Analysts Set Expectations for Qiagen Q2 Earnings - Defense World
Ameriprise Financial Inc. Grows Stake in Qiagen (NYSE:QGEN) - Defense World
QIAGEN NV : Berenberg gives a Buy rating - marketscreener.com
Cetera Investment Advisers Acquires 1,418 Shares of Qiagen (NYSE:QGEN) - Defense World
Qiagen NV (QGEN) Trading 4% Higher on May 27 - GuruFocus
QIAGEN NV : Receives a Buy rating from DZ Bank - marketscreener.com
Cell-Free DNA Isolation and Extraction Market - GlobeNewswire Inc.
Europe Digital PCR Industry Research Report 2025: Increased Use of Digital-PCR-Based Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plans - GlobeNewswire Inc.
Qiagen and ID Solutions Partner to Enhance Digital PCR Assays for Oncology Research - Insider Monkey
QIAGEN expands digital PCR oncology research portfolio through p - GuruFocus
QGEN Stock Might Gain Following New Partnership With ID Solutions - TradingView
Qiagen and ID Solutions collaborate on dPCR assays for oncology research - Medical Device Network
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions - Silicon Canals
QIAGEN (QGEN) Expands dPCR Assay Availability Through New Partnership | QGEN Stock News - GuruFocus
QIAGEN (QGEN) Expands dPCR Assay Availability Through New Partne - GuruFocus
miRNA Sequencing and Assays Market Research Report 2025-2030 with Focus on 25+ Major Players Such as Abcam, HTG Molecular Diagnostics, Illumina, Lexogen, Meridian Bioscience - GlobeNewswire Inc.
QIAGEN acquires AI-powered software, Genoox - MSN
Here's Why Qiagen (QGEN) is a Strong Momentum Stock - Yahoo Finance
Qiagen Receives Notification of BlackRock’s Voting Rights - TipRanks
QIAGEN Stock Gains Following the Acquisition of Genoox - MSN
Qiagen Stock Beats Earnings, But Its Expensive Valuation Caps Upside Potential (NYSE:QGEN) - Seeking Alpha
Some Investors May Be Willing To Look Past Qiagen's (NYSE:QGEN) Soft Earnings - Yahoo Finance
BlackRock Increases Stake in Qiagen, Influencing Market Dynamics - TipRanks
Qiagen Receives Significant Voting Rights Notification from AFM - TipRanks
Qiagen’s Voting Rights Announcement Highlights BlackRock’s Influence - TipRanks
QIAGEN acquires Genoox to enhance genetic data analysis By Investing.com - Investing.com Nigeria
Qiagen Releases Q1 2025 Financial Report Highlighting Asset Decline - TipRanks
Pluri (NASDAQ:PLUR) & Qiagen (NYSE:QGEN) Head to Head Contrast - Defense World
Qiagen (QGEN) Expands Genomic Capabilities with Genoox Acquisiti - GuruFocus
PTA-CMS: QIAGEN N.V.: Release of a capital market information - TradingView
Qiagen Acquires Genoox for $70 Million - marketscreener.com
QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software - 01net
QIAGEN acquires Genoox to enhance genetic data analysis - Investing.com Australia
Qiagen Acquires Genoox For $70 Million Plus $10 Million In Milestones - marketscreener.com
Qiagen (NYSE:QGEN) Shares Sold by First Trust Advisors LP - Defense World
Analysts Are Updating Their Qiagen N.V. (NYSE:QGEN) Estimates After Its First-Quarter Results - simplywall.st
Is Qiagen (NYSE:QGEN) A Risky Investment? - simplywall.st
The Qiagen N.V. (NYSE:QGEN) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Qiagen N.V. (NYSE:QGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
QIAGEN Reports Strong Q1 2025 Results and Plans Dividend Initiation - TipRanks
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
1.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):